insulin aspart versus insulin lispro

This entry refers to a comparative clinical trial conducted by the Joslin Diabetes Center evaluating two rapid-acting insulin analogs: insulin aspart and insulin lispro. Both are biologic, recombinant versions of human insulin designed to provide rapid onset and short duration of action. Insulin aspart (developed by Novo Nordisk) and insulin lispro (developed by Eli Lilly) both act as agonists at the insulin receptor, regulating glucose metabolism by facilitating cellular glucose uptake and inhibiting hepatic glucose production. The specific study (NCT00263328) was a crossover trial in patients with type 1 diabetes mellitus using continuous subcutaneous insulin infusion (CSII) to compare glycemic stability and the incidence of catheter occlusions between the two products, particularly when infusion sets are used for longer than the standard 72 hours.

Brand names

NovoLogNovoRapidHumalog

Other names

insulin aspartinsulin lispro